The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine

American Journal of Tropical Medicine and Hygiene

Volumn 73, Issue 2, 2005, Pages 272-275

  Yardley, Vanessa ^a   Croft, Simon L ^a   De Doncker, Simonne ^b   Dujardin, Jean Claude ^b   Koirala, Siddhartha ^d   Rijal, Suman ^d   Miranda, Cesar ^c   Llanos Cuentas, Alejandro ^c   Chappuis, Francois ^e  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^d B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIMONY GLUCONATE; MILTEFOSINE; PROTOZOAL DNA;

ADOLESCENT; ADULT; ANTIPROTOZOAL ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG SENSITIVITY; FEMALE; HUMAN; IN VITRO STUDY; LEISHMANIA; LEISHMANIASIS; MALE; NONHUMAN; PARASITE IDENTIFICATION; PERU; POLYMERASE CHAIN REACTION; PROMASTIGOTE; PUNCH BIOPSY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIA GUYANENSIS; LEISHMANIA LAINSONI; LEISHMANIA MEXICANA; LEISHMANIASIS MEXICANA;

EID: 24644501726     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2005.73.272     Document Type: Article

References (18)

1. Croft SL, Coombs GH, 2003. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19: 502-508.
2. Croft SL, Seifert K, Duchene M, 2003. Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol 126: 165-172.
3. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746.
4. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J, 2001. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33: E57-E61.
5. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38: 1266-1272.
6. Burroughs P, 2004. AEterna through its subsidiary Zentaris signs partnership with Roche in Brazil for new treatment of leishmaniasis, a devastating tropical diseases. Available at http://217.160.S7.239/en/content/ downloads/20040202final.pdf.
7. Croft SL, Yardley V, Kendrick H, 2002. Drug sensitivity of Leishmania species: some unresolved problems. Trans R Soc Trop Med Hyg 96: S127-S129.
8. Escobar P, Matu S, Marques C, Croft SL, 2002. Sensitivities of Leishmania species to hexadecylphophocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B. Acta Trop 81: 151-157.
9. Evans DA, 1993. In vitro cultivation and biological cloning of Leishmania. Methods Mol Biol 21: 29-41.
10. Coderre JA, Beverley SM, Schimke RT, Santi DV, 1983. Overproduction of a bifunctional thymidylate synthetase-dihydrofolate reductase and DNA amplification in methotrexate-resistant Leishmania tropica. Proc Natl Acad Sci U S A 80: 2132-2136.
11. Dey T, Afrin F, Anam K, Ali N, 2002. Infectivity and virulence of Leishmania donovani promastigotes: a role for media, source, and strain of parasite. J Eukaryot Microbiol 49: 270-274.
12. Garcia AL, Kindt A, Llanos A, Bermudez H, Arevalo J, Banuls AL, Tibayrenc M, de Doncker S, Le Ray D, Dujardin J-C, 2005. American tegumentary leishmaniasis: antigen-gene polymorphism, taxonomy and clinical pleomorphism. Infection, Genetics and Evolution 8: 109-116.
13. Victoir K, De Doncker S, Cabrera L, Alvarez E, Arevalo J, Llanos-Cuentas A, Le Ray D, Dujardin JC, 2003. Direct identification of Leishmania species in biopsies from patients with American tegumentary leishmaniasis. Trans R Soc Trop Med Hyg 97: 80-87.
14. Tintaya KWQ, Ying X, Dedet JP, Rijal D, Bolle XD, Dujardin JC, 2004. Antigen genes for molecular epidemiology of leishmaniasis: polymorphism of cysteine proteinase b and surface metalloprotease gp63 in the Leishmania donovani complex. J Infect Dis 189: 1035-1043.
15. Garcia L, Kindt A, Bermudez H, Llano-Cuentas A, Doncker SD, Arevalo J, Tintaya KWQ, Dujardin J-C, 2004. Culture-independent species typing of neotropical Leishmania for clinical validation of a PCR-based assay targeting heat shock protein 70 genes. J Clin Microbiol 42: 2294-2297.
16. Perez-Victoria JM, Perez-Victoria FJ, Parodi-Talice A, Jimenez IA, Ravelo AG, Castanys S, Gamarro F, 2001. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob Agents Chemother 45: 2468-2474.
17. Seifert K, Matu S, Javier Perez-Victoria F, Castanys S, Gamarro F, Croft SL, 2003. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 22: 380-387.
18. Aubouy A, Bakary M, Keundjian A, Mbomat B, Makita JR, Migot-Nabias F, Cot M, Le Bras J, Deloron P, 2003. Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. Antimicrob Agents Chemother 47: 231-237.